SAVED
File name .JPG
File alt. text
Image should be px wide x px tall.
Select Image
home - Pancreas - Pancreatic Cancers - Mucinous Cystadenoma Written by Dr Sebastian Zeki
Knowledge


Knows the presentation investigation and staging of pancreatic
cancer

Recognises the importance of considering and being able to identify
uncommon pancreatic tumours (such as neuroendocrine or
intrapapillary mucinous tuours)

Knows the range of potential therapies and recognises the factors
that make such tumours potentially operable or inoperable

Knows the prevalence and natural history of benign cysts/serous
cystadenoma and potentially malignant cystic lesions

Knows the options for palliative treatment
Skills
Shows ability to sequence investigations appropriately
Understands value of multi-disciplinary team
Recognises the importance of considering possibility that the tumour
is unusual

Behaviours
Communicates effectively within the multi-disciplinary team and with
the patient and their family

Mucinous Cystadenoma

Mucinous cystadenoma Mucin Mucin Mucin Macrocystic spaces lined by mucous-secreting cellsVery cellular collagenous and sometimes calcified stromal layer beneath epithelium with oestrogen/progesterone staining spindle cells EpidemiologyThey have a Malignant/ potential to be malignant.Middle aged woman are the most common patients.It is the Most common of the cystic neoplasms.Macrocystic spaces produce mucin within a mass is characteristic.It is Murderously difficult to make diagnosis from biopsy (cells often denuded).It is located in body or tail. Classification:-MCN with low-grade dysplasia.-MCN with moderate dysplasia.-MCN with high-grade dysplasia (which can be in situ or invasive- (17% of HGD and behaves as ductal adenocarcinoma). Categories are based on the degree of epithelial dysplasia. Written by Dr Sebastian Zeki

Related Stories

•Transcriptomic landscape of transposable elements reveals LTR7-PLAAT4 as a potential oncogene and therapeutic target in pancreatic adenocarcinoma

•Radiopathomics Signature for Prognosis and Prediction of Chemotherapy Benefit in Unresectable Pancreatic Cancer

•Graphene Quantum Dots in Cancer Diagnostics and Therapeutics: Advances in Biosensing, Imaging, and Treatment Applications

•Cancer-Associated Fibroblast-Centric Risk Model Predicts Immunotherapy Resistance in Pancreatic Cancer and Reveals PLOD2 as a Key Stromal Therapeutic Target

•A novel pan class-I glucose transporter inhibitor DRB18 exhibits synergistic effects with paclitaxel in vitro and in vivo against human non-small cell lung cancer